中農立華(603970.SH):K胺是合成氯蟲苯甲酰胺的關鍵中間體之一
格隆匯6月9日丨中農立華(603970.SH)在互動平台表示,K胺是合成氯蟲苯甲酰胺的關鍵中間體之一。氯蟲苯甲酰胺作為全球第一大殺蟲劑品種,自 2022年8月實現國產化以來,公司基於農藥流通領域的行業積澱與農業現代化服務的市場趨勢,對該產品進行戰略級規劃佈局。依託"國家隊"供應鏈優勢,公司已與國內頭部原藥生產企業簽署深度合作協議,其具備行業領先的氯蟲苯甲酰胺合成技術及產能安排,雙方協作構建從採購、倉儲到分銷的全程服務體系。此外,公司為富美實、拜耳等跨國農化企業提供涵蓋訂單管理、物流配送等一體化供應鏈解決方案。與此同時,立華國際在巴西、阿根廷等二十餘個國家地區啟動氯蟲產品登記矩陣建設,目前公司已完成該產品在多個國家的毒理數據備案,加速推進自主品牌製劑產品在海外市場的商業化落地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.